Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William D Figg

Showing results (31-40 of 638) with videos related to

Pageof 64
Sort By:
Cancers|March 10, 2022
Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is WarrantedTristan M Sissung, William D Figg
Cancer Biology & Therapy|July 16, 2004
Mutations in the EGFR: the importance of genotypingDouglas K Price, William D Figg
The Journal of Urology|August 12, 2005
In vivo models of prostate cancer metastasis to boneArun S Singh, William D Figg
CA: a Cancer Journal for Clinicians|June 18, 2010
Angiogenesis inhibitors: current strategies and future prospectsKristina M Cook, William D Figg
Cancer Biology & Therapy|August 20, 2010
A novel regulator (USP10) of p53: Implications for tumor suppression and therapeutic targetingKelie M Reece, William D Figg
Family & Community Health|April 6, 2022
Commentary: Electronic Nicotine Delivery Systems: Seeing Through the CloudsTristan M Sissung, William D Figg
Cancer Biology & Therapy|October 3, 2006
The quantification of PSA mRNA copies in pathologically normal pelvic lymph nodes is a viable prognostic indicatorJacob N Beverage, William D Figg
Cancer Biology & Therapy|May 2, 2007
Benefits of the combination of thalidomide plus cyclophosphamide in hormone refractory prostate cancer patientsTania Al-Chalabi, William D Figg
Pharmacotherapy|September 27, 2006
Chemoprevention in prostate cancerHoward L Parnes, William D Figg
The Oncologist|September 23, 2024
Clinical trial results: each patient's participation should countWilliam D Figg, Susan E Bates
Pageof 64

Showing results (31-40 of 638) with videos related to

Sort By:
Pageof 64
Cancers|March 10, 2022
Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is WarrantedTristan M Sissung, William D Figg
Cancer Biology & Therapy|July 16, 2004
Mutations in the EGFR: the importance of genotypingDouglas K Price, William D Figg
The Journal of Urology|August 12, 2005
In vivo models of prostate cancer metastasis to boneArun S Singh, William D Figg
CA: a Cancer Journal for Clinicians|June 18, 2010
Angiogenesis inhibitors: current strategies and future prospectsKristina M Cook, William D Figg
Cancer Biology & Therapy|August 20, 2010
A novel regulator (USP10) of p53: Implications for tumor suppression and therapeutic targetingKelie M Reece, William D Figg
Family & Community Health|April 6, 2022
Commentary: Electronic Nicotine Delivery Systems: Seeing Through the CloudsTristan M Sissung, William D Figg
Cancer Biology & Therapy|October 3, 2006
The quantification of PSA mRNA copies in pathologically normal pelvic lymph nodes is a viable prognostic indicatorJacob N Beverage, William D Figg
Cancer Biology & Therapy|May 2, 2007
Benefits of the combination of thalidomide plus cyclophosphamide in hormone refractory prostate cancer patientsTania Al-Chalabi, William D Figg
Pharmacotherapy|September 27, 2006
Chemoprevention in prostate cancerHoward L Parnes, William D Figg
The Oncologist|September 23, 2024
Clinical trial results: each patient's participation should countWilliam D Figg, Susan E Bates
Pageof 64